JP2005525408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525408A5 JP2005525408A5 JP2004500853A JP2004500853A JP2005525408A5 JP 2005525408 A5 JP2005525408 A5 JP 2005525408A5 JP 2004500853 A JP2004500853 A JP 2004500853A JP 2004500853 A JP2004500853 A JP 2004500853A JP 2005525408 A5 JP2005525408 A5 JP 2005525408A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disorder
- retinal
- edema
- macular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 230000002207 retinal effect Effects 0.000 claims 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 206010030113 Oedema Diseases 0.000 claims 4
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims 4
- 206010059245 Angiopathy Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 201000000159 corneal neovascularization Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 206010062198 microangiopathy Diseases 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- SOYCMDCMZDHQFP-UHFFFAOYSA-N amfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=CC=C1 SOYCMDCMZDHQFP-UHFFFAOYSA-N 0.000 claims 1
- 229950008930 amfenac Drugs 0.000 claims 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 claims 1
- 229960001002 nepafenac Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37742902P | 2002-05-03 | 2002-05-03 | |
| PCT/US2003/011769 WO2003092669A2 (en) | 2002-05-03 | 2003-04-16 | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005525408A JP2005525408A (ja) | 2005-08-25 |
| JP2005525408A5 true JP2005525408A5 (https=) | 2006-04-20 |
Family
ID=29401494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004500853A Pending JP2005525408A (ja) | 2002-05-03 | 2003-04-16 | アンフェナクまたはネパフェナクを用いる血管内皮増殖因子媒介性血管障害の処置方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050143468A1 (https=) |
| EP (1) | EP1507522A2 (https=) |
| JP (1) | JP2005525408A (https=) |
| KR (1) | KR20040101499A (https=) |
| CN (1) | CN1649575A (https=) |
| AU (1) | AU2003231730A1 (https=) |
| BR (1) | BR0309747A (https=) |
| CA (1) | CA2483275A1 (https=) |
| MX (1) | MXPA04010132A (https=) |
| PL (1) | PL373787A1 (https=) |
| WO (1) | WO2003092669A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060142236A1 (en) * | 1994-05-31 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US20090087424A1 (en) * | 2004-11-26 | 2009-04-02 | Noriko Miyamoto | Modulating Retinal Pigmented Epithelium Permeaion By Inhibiting Or Activating VEGFR-1 |
| TWI358290B (en) | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| HRP20100559T1 (hr) * | 2005-11-29 | 2010-11-30 | Glaxosmithkline Llc | Liječenje neovaskularnih poremećaja oka, poput makularne degeneracije, angioidnih strija, uveitisa i edema makule |
| JP2012062258A (ja) * | 2010-09-14 | 2012-03-29 | Oriza Yuka Kk | 血管新生抑制剤及びそれを用いた眼疾患予防・治療剤 |
| TW202023575A (zh) * | 2011-09-16 | 2020-07-01 | 美商遠景生物製藥股份有限公司 | 安定之普維酮—碘組成物 |
| JP6427843B2 (ja) * | 2013-03-29 | 2018-11-28 | 株式会社ＡｓｋＡｔ | 眼疾患治療剤 |
| US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE400966B (sv) * | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
| US4313949A (en) * | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
| US4254146A (en) * | 1979-10-18 | 1981-03-03 | A. H. Robins Company, Inc. | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters |
| US4503073A (en) * | 1981-01-07 | 1985-03-05 | A. H. Robins Company, Incorporated | 2-Amino-3-(alkylthiobenzoyl)-phenylacetic acids |
| US4568695A (en) * | 1983-12-07 | 1986-02-04 | A. H. Robins Company, Incorporated | 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor |
| US4683242A (en) * | 1985-10-28 | 1987-07-28 | A. H. Robins Company, Incorporated | Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters |
| CA1325382C (en) * | 1988-01-27 | 1993-12-21 | Takahiro Ogawa | Locally administrable therapeutic composition for inflammatory disease |
| US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| US6066671A (en) * | 1997-12-19 | 2000-05-23 | Alcon Laboratories, Inc. | Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides |
| AU782386C (en) * | 1999-08-31 | 2006-08-10 | Brigham And Women's Hospital | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| US6416777B1 (en) * | 1999-10-21 | 2002-07-09 | Alcon Universal Ltd. | Ophthalmic drug delivery device |
| AR030345A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes relacionados con angiogenesis |
| AU2002247284A1 (en) * | 2001-04-02 | 2002-10-15 | Alcon, Inc. | Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac |
-
2003
- 2003-04-16 BR BR0309747-1A patent/BR0309747A/pt not_active Application Discontinuation
- 2003-04-16 AU AU2003231730A patent/AU2003231730A1/en not_active Abandoned
- 2003-04-16 CN CNA038094797A patent/CN1649575A/zh active Pending
- 2003-04-16 KR KR10-2004-7016542A patent/KR20040101499A/ko not_active Withdrawn
- 2003-04-16 CA CA002483275A patent/CA2483275A1/en not_active Abandoned
- 2003-04-16 MX MXPA04010132A patent/MXPA04010132A/es unknown
- 2003-04-16 WO PCT/US2003/011769 patent/WO2003092669A2/en not_active Ceased
- 2003-04-16 PL PL03373787A patent/PL373787A1/xx not_active Application Discontinuation
- 2003-04-16 EP EP03747593A patent/EP1507522A2/en not_active Withdrawn
- 2003-04-16 JP JP2004500853A patent/JP2005525408A/ja active Pending
- 2003-04-16 US US10/511,414 patent/US20050143468A1/en not_active Abandoned
- 2003-04-16 US US10/417,466 patent/US20030207941A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jonas et al. | Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases | |
| Casson | Medical therapy for glaucoma: A review | |
| AU777727B2 (en) | Method for treating and/or preventing retinal diseases with sustained release corticosteroids | |
| JP2006503913A5 (https=) | ||
| WO2008111497A1 (ja) | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 | |
| Velez et al. | New developments in sustained release drug delivery for the treatment of intraocular disease | |
| JP2003515528A5 (https=) | ||
| RU2009145939A (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
| JP2005509623A5 (https=) | ||
| CA2502437A1 (en) | Method and composition containing latanoprost for treating ocular hypertension and glaucoma | |
| JP2010513542A5 (https=) | ||
| HRP20100559T1 (hr) | Liječenje neovaskularnih poremećaja oka, poput makularne degeneracije, angioidnih strija, uveitisa i edema makule | |
| JP2015025011A5 (https=) | ||
| JP2012505162A5 (https=) | ||
| JP2007535367A5 (https=) | ||
| CA2454976A1 (en) | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient | |
| JP2005525408A5 (https=) | ||
| WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
| WO2002009702A3 (en) | Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure | |
| MX2020007948A (es) | Medicamento para prevenir o tratar una enfermedad oftalmica asociada con neovascularizacion intraocular mejorada y/o permeabilidad vascular intraocular. | |
| EP1074258A3 (en) | Methods and compositions for treating diseases and conditions of the eye | |
| JP2007527417A5 (https=) | ||
| JP2009519962A5 (https=) | ||
| JP2013513606A5 (https=) | ||
| RU2005129278A (ru) | Препаративные глюкокортикоиды для лечения патологического ангиогенеза глаз |